No registrations found.
Source
Brief title
Health condition
Osteoarthritis & metabolic syndrome
Sponsors and support
Intervention
No registrations found.
Outcome measures
Primary outcome
Main endpoint for patients with OA & MetS is the difference between the mean change in the combined scores on pain, stiffness and function, combined in the WOMAC index for OA, from 0-16 weeks in the intervention and control groups.
Secondary outcome
General:
Self-reported physical (fatigue, pain intensity, pain interference, physical function, sleep disturbance), mental (anxiety, depression) and social (ability to participate in social roles & activities) health using the validated Dutch-Flemish Patient Reported Outcomes Measurement Information System (PROMIS®). This system uses computer adaptive testing (CAT) methods to evaluate physical, mental and social health. With CAT PROMIS® is able the dynamically select items based upon the respondent’s previous answers. With this method measurement is limited to 3-7 questions to obtain valid outcomes.
Body composition & metabolism:
Body weight (with clothes, no shoes, kg)
Body height (cm)
BMI (kg/m2)
Waist circumference (cm, at approximate midpoint between the lower margin of the last palpable rib and the top of the iliac crest).
Total fat free mass (DEXA, kg & % of body weight)
Total muscle mass (DEXA, kg & % of body weight)
Total fat mass (DEXA, kg & % of body weight)
50 OA patients (30 from the intervention group and 20 from the control group) will be recruited for MRI examination of:
- visceral adipose tissue (VAT), spectroscopy will be used to identify fatty acid distribution
- liver fat content, spectroscopy will be used to identify fatty acid distribution
- intramuscular fat mass in the thigh muscle
- synovitis and size of the infrapatellar fat pad, spectroscopy will be used to identify fatty acid distribution
Based on earlier research small changes seem to occur in 6 months, which is – together with financial motivations – the rationale to use a smaller control group. Total time in the MRI scanner is estimated to be maximum 60 minutes.
Physical performance:
Hand grip strength (dynamometer, kg/force), measured as the maximum grip score of 6 trials (3 left, 3 right), with the subject encouraged, in a seated position, forearms rested on the arms of the chair, wrist just over the end of the arm of the chair, in a neutral position, thumb facing upwards, feet flat on the floor, alternating sides.
Function (get-up-and-go test [GUG-test], seconds), measured as the time needed by the subject to get up from a chair without using the hands and to walk as fast as possible to a line 15.2 meters away from the chair.
Physical activity level (PAL, as coefficient related to base metabolic rate [BMR]), measured with a pedometer.
Metabolic:
Blood pressure (mmHg)
Heart rate variability, performed at baseline, at 4 months and at the end of the extension study. Measured by a 5-minute electrocardiography (ECG) in supine position and a 2-minute ECG during an orthostatic stress test.
Lipid profile (total cholesterol, LDL, HDL, triglycerides in blood, mmol/l)
Fasting glucose (blood, mmol/l)
HbA1c (blood, mmol/mol))
Pathogenesis:
Erythrocyte sedimentation rate (ESR)
Gut microbiota composition (faeces, colony forming units [CFU]/g), collected by the subject at home using an in-house collection kit, frozen, transferred to Reade and brought to -80o C at Reade within 24 hours for later analysis.
Saliva microbiota composition (saliva, CFU/g), collected by the subject at home using an in-house collection kit, frozen, transferred to Reade and brought to -80o C at Reade within 24 hours for later analysis. A short questionnaire will be used to determine self-reported oral health.
Metabolome change (blood and urine, percentage change from baseline), collected during measurement visits at Reade and frozen at -80o C for later analysis. Later analysis of microbiome and metabolome samples (including measurement of short chain fatty acids) will be based on the at that time state of the art methods.
Background summary
Rationale:
An unhealthy lifestyle is associated with a higher risk of chronic diseases and conditions such as osteoarthritis (OA) and metabolic syndrome (MetS), with the latter being highly prevalent in OA patients. Low-grade inflammation is often present in people with unhealthy lifestyles and may be a key factor in the pathogenesis of chronic inflammatory diseases. Current treatment of OA mainly consists of medication, exercise therapy and weight loss. Combining different types of non-pharmacological therapies such as diet, exercise and stress management has shown synergizing effects in other chronic diseases. Whole foods plant-based diets (WFPDs) have shown promising results for the treatment of OA and metabolic syndrome but were not yet combined with other lifestyle interventions.
Objective:
To investigate the effect of a multidisciplinary lifestyle program, based on a WFPD, exercise and stress management on pain, function and stiffness (WOMAC-score) in patients with OA & MetS. A one-year extension study will investigate continued adherence to lifestyle changes and measure to what extent it is possible to taper drug therapy for OA-patients with less perceived pain.
Study design:
A 16-week randomized single-blind controlled trial (RCT), comparing a multidisciplinary lifestyle program with usual care in patients with OA & MetS (n=80). The control group will be placed on a waiting list to receive the intervention after 16 weeks. After completion of the lifestyle program, all patients will be followed in a two-year extension study.
Study population:
Patients with OA in hip and/or knee & MetS.
Intervention:
Personal counselling on diet and exercise, followed by 10 meetings in groups of 15 people with theoretical and practical training on a WFPD, exercise and stress management. The control group receives usual care. During the 16-week program the medication remains unchanged. During the two-year extension program subjects have 6 additional group meetings and – in case of less perceived pain – medication will be tapered.
Main study parameters/endpoints:
The primary outcomes are: difference in mean change between intervention- and control group for the WOMAC score. For the two-year extension study the change in adherence from 0-24 months is the main endpoint.
Study objective
A 16-week multidisciplinary lifestyle program, based on (1) a WFPD, (2) exercise and (3) stress management
H0: has no effect on the WOMAC in patients with hip- and/or knee osteoarthritis and metabolic syndrome, in comparison with usual care.
H1: lowers the WOMAC (improvement) in patients with hip- and/or knee osteoarthritis and metabolic syndrome, in comparison with usual care.
Study design
Start RCT: May 2019. End RCT: summer 2021. End extension study: summer 2023.
Intervention
During the first visit, subjects will be randomized and baseline measurements will be taken. The first visit will be concluded with a personal intake meeting with a registered dietician and a physiotherapist to determine personal objectives (i.e. weight loss), as well as abilities and limitations regarding exercise.
During the 16-week lifestyle program subjects will meet 10 times (weekly from week 1-9 and the last meeting in week 13, with minor rescheduling in case of holidays) in groups of maximum 15 people. Participants are invited to bring their partner/spouse (or someone else who is able to support the patient in this program) to the first meeting (cooking class).
During all meetings (duration 2- 3 hours) subjects will receive theoretical and/or practical training, based on protocols tested in previous studies on the following topics:
1. Whole foods plant-based diet (e.g. workshops cooking).
2. Exercise (e.g. brisk walking and/or muscle strengthening exercises), based on the Dutch physical activity guidelines 2017.
3. Stress management (e.g. relaxation exercises).
Inclusion criteria
Patients ≥ 18 years.
OA in hip and/or knee, diagnosed according to the clinical criteria or the American College of Rheumatology (without age-criterion):
- Hip OA: hip pain in combination with either (1) hip internal rotation ≥15º, pain on hip internal rotation and morning stiffness of the hip ≤60 minutes, or (2) hip internal rotation <15º and an ESR ≤ 45 mm/hour (if ESR not available, substitute hip flexion ≤115º).
- Knee OA: knee pain and 5 (or 3 if no laboratory) of the following criteria: (1) stiffness <30 minutes, (2) crepitus, (3) bony tenderness, (4) bony enlargement, (5) no palpable warmth, (6) ESR <40 mm/hour, (7) RF<1:40, (8) synovial fluid findings of OA.
- In addition radiography (<2 years, most patients come from an existing cohort study in which radiographs are included) will be used to classify the OA according to the Kellgren-Lawrence grading scheme.
Metabolic syndrome according to the criteria defined by the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III): when 3 or more of the following criteria are met: (1) waist circumference ≥102 (♂) / ≥88 (♀) cm, (2) fasting glucose ≥6.1 mmol/l, (3) triglycerides ≥1.7 mmol/l, (4) HDL <1.04 (♂) / <1.29 (♀) mmol/l, (5) blood pressure ≥130/85 mmHg.
Exclusion criteria
Already following a (near-)vegan diet.
Pregnancy.
Absolute contra-indication for exercise therapy: resting systolic blood pressure of >200 mmHg or diastolic blood pressure of >115 mmHg, acute myocardial infarction within the last 3 months, chest pain at rest/before exercise, other severe cardiac diseases (e.g. symptomatic aortic stenosis, severe cardiac arrhythmias).
Underweight (BMI<18,5 kg/m2).
In case of smoking, unwillingness to stop smoking for at least the duration of the study.
Low e-health competencies (lowest proficiency according to Pharos quick scan, see appendix B).
Insufficient comprehension of Dutch language.
Inability to be scheduled for therapy or meetings.
Concurrent presence of other forms of joint disease than OA, RA or ACPA positive arthralgia.
Psychiatric disease.
Total arthroplasty of hip or knee scheduled.
No informed consent.
Design
Recruitment
IPD sharing statement
Plan description
The investigators have the intention to publish the results in a scientific journal.
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
NTR-new | NL7801 |
CCMO | NL66649.048.18 |